“The Prospective Randomized Trial Evaluating the Efficacy of the Mitomycin C and Cisplatin Regimen (MP) versus Standard First-Line Chemotherapy in Patients With Advanced BRCA1 2-Associated Ovarian Cancer (NCT04747717)”. Voprosy Onkologii, vol. 68, no. 5, Oct. 2022, pp. 628-3, https://doi.org/10.37469/0507-3758-2022-68-5-628-638.